CHPT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CHPT is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some improving sentiment from analysts and hedge funds, but the technical trend is still bearish and the options data does not show a strong bullish conviction. If forced to act now, the better call is to hold and wait for clearer technical confirmation rather than buying immediately.
The current technical setup is weak. MACD histogram is negative at -0.154 and still contracting, RSI_6 is 40.801, which is neutral to slightly weak, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price at 5.97 is below the pivot level of 6.637 and only slightly above support at 5.365, which suggests the stock is still in a downtrend and not showing a confirmed reversal.
Hedge funds have also been buying, with buying amount up 212.50% over the last quarter.
The main negatives are the bearish technical trend and the lack of a clear turnaround signal. No AI Stock Pick or SwingMax signal is present. Insider trading is neutral, there is no congress trading data, and the financial snapshot is unavailable, so there is no strong fundamental confirmation to support a confident long-term buy at the current price.
Latest quarter financials could not be assessed because the financial snapshot data returned an error. As a result, there is no usable latest-quarter revenue or profitability detail here. Based on the available analyst commentary, the company is viewed as making progress on cost discipline and may support double-digit revenue growth beyond FY27, but that is a longer-dated thesis rather than an immediate earnings-based buy signal.
Analyst sentiment is improving modestly. UBS raised its price target from $7 to $8 and maintained a Neutral rating, while TD Cowen raised its target from $7 to $7.50 and kept a Hold rating after FQ1 results. The Wall Street pros view is cautiously constructive on improving execution and longer-term revenue growth potential, but the cons view remains that ratings are still only Neutral/Hold, so analysts are not broadly recommending an aggressive buy.
